Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin

Journal of Clinical Pharmacology

Volumn 43, Issue 6, 2003, Pages 586-590

  Chow, Sheryl L ^a   Zammit, Kimberly ^b   West, Kathleen ^b   Dannenhoffer, MaryAnne ^b   Lopez Candales, Angel ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b NONE

Author keywords

Antifactor Xa; Enoxaparin; Low molecular weight heparin; Renal function

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION FUNCTION; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DRUG CLEARANCE; DRUG EFFICACY; FEMALE; HUMAN; KIDNEY FUNCTION; LUNG EMBOLISM; MALE; MULTIPLE DRUG DOSE; UNSTABLE ANGINA PECTORIS;

EID: 0038582288     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003253420     Document Type: Article

References (20)

1. Eriksson BI, Kalebo P, Anthmyr BO, Wadenvik H, Tengborn L, Risberg B: Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement: comparison of low molecular weight heparin and unfractionated heparin. J Bone Joint Surg 1991;73(4):484-493.
2. Simonneau G, Charbonnier B, Decousus H, Planchon B, Ninet J, Sie P, et al: Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal vein thrombosis. Arch Intern Med 1993;153:1541-1546.
3. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group: Low-molecular weight heparin during instability in coronary artery disease. Lancet 1996;347:561-568.
4. Klein W: Low molecular weight heparin in the initial and prolonged treatment of unstable coronary artery disease: the Fragmin in Unstable Coronary Heart Disease study (FRIC) [abstract]. Eur Heart J 1996;17(Suppl.):306.
5. Cohen M, Demers C, Gurfinkel EP, et al: A comparison of low-molecular-weight heparin and unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-452.
6. Cziraky MJ, Spinler SA: Low molecular weight heparins for the treatment of deep vein thrombosis. Clin Pharm 1993;12:892-899.
7. Hirsh J, Levine MN: Low molecular weight heparin. Blood 1992;79:1-17.
8. Barrowcliffe TW: Low molecular weight heparin(s). Br J Haematol 1995;90:1-7.
9. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L: Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995;108(Suppl. 4):258S-275S.
10. Boneau B, Caranobe C, Sie P: Pharmacokinetics of heparin and low molecular weight heparin, in: Hirsh J (ed.), Bailliere's Clinical Haematology, Antithrombotic Therapy. London: Bailliere Tindall, 1990;531-544.
11. Cadroy Y, Pourrat J, Baladre M, Saivin S, Houin G, Montastruc J, et al: Delayed elimination of enoxaparine in patients with chronic renal insufficiency. Thrombosis Res 1991;63:385-390.
12. Buckley MM, Sorkin EM: Enoxaparin: a review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders. Drugs 1992;44:465-497.
13. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-470.
14. STACHROM® Heparin Assay [product information], Diagnostica Stago, France, 1996.
15. Brophy DF, Wazny LD, Gehr TB, Cornstock TJ, Venitz J: The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease. Pharmacotherapy 2001;21(2):169-174.
16. Collet JP, Montalescot G, Choussat R, Lison L, Ankri A: Enoxaparin in unstable angina patients with renal failure. Int J Cardiol 2001;80:81-82.
17. Lovenox® [product information], Aventis Pharmaceuticals, Bridgewater, NJ, 2001.
18. Gerlach AT, Pickworth KK, Seth SK, Tanna SB, Barnes JE: Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy 2000;20(7):771-775.
19. Becker RC, Spencer FA, Gibson M, et al: Influence of patient characteristics and renal function of factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 2002;143:753-759.
20. Laposata M, Green D, Van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC: College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy. Arch Path Lab Med 1998;122:799-807.